Nov 13, 2018 9:05am EST SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
Oct 23, 2018 9:00am EDT SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp
Oct 15, 2018 9:26am EDT SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
Sep 04, 2018 8:00am EDT SCYNEXIS, Inc. Presents Ibrexafungerp Data at the 2018 ESCMID/ASM Conference on Drug Development
Aug 09, 2018 4:15pm EDT SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update
